Bempedoic acid improves outcomes in statin-intolerant patients

The cholesterol-lowering drug bempedoic acid reduced the combined rate of major adverse cardiovascular events by 13%, meeting its primary endpoint in a large study of patients with high cholesterol who were unable to tolerate statins, according to research being presented at the American College of Cardiology’s Annual Scientific Session Together With the World Congress of Cardiology.